1. Home
  2. QNST vs DRUG Comparison

QNST vs DRUG Comparison

Compare QNST & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuinStreet Inc.

QNST

QuinStreet Inc.

N/A

Current Price

$12.16

Market Cap

870.0M

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$72.37

Market Cap

707.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QNST
DRUG
Founded
1999
2019
Country
United States
United States
Employees
N/A
25
Industry
Business Services
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
870.0M
707.1M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
QNST
DRUG
Price
$12.16
$72.37
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$24.75
$124.00
AVG Volume (30 Days)
828.8K
78.6K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.94
N/A
Revenue
$282,140,000.00
N/A
Revenue This Year
$18.59
N/A
Revenue Next Year
$14.96
N/A
P/E Ratio
$12.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$23.18
52 Week High
$19.53
$123.75

Technical Indicators

Market Signals
Indicator
QNST
DRUG
Relative Strength Index (RSI) 51.57 37.05
Support Level $10.79 $72.06
Resistance Level $12.62 $91.00
Average True Range (ATR) 0.46 4.68
MACD 0.16 -1.03
Stochastic Oscillator 75.41 15.05

Price Performance

Historical Comparison
QNST
DRUG

About QNST QuinStreet Inc.

QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: